¼¼°èÀÇ Ç¥º» ¼öÁý Ä«µå ½ÃÀå
Specimen Collection Cards
»óǰÄÚµå : 1777573
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 392 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ç¥º» ¼öÁý Ä«µå ½ÃÀåÀº 2030³â±îÁö 5¾ï 5,970¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 4¾ï 5,080¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Ç¥º» ¼öÁý Ä«µå ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 3.7%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 5¾ï 5,970¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Ç÷¾×Àº CAGR 3.7%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 2¾ï 2,110¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ÿ¾× ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 2.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 2,280¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ç¥º» ¼öÁý Ä«µå ½ÃÀåÀº 2024³â¿¡ 1¾ï 2,280¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀ» 6.8%·Î 2030³â±îÁö 1¾ï 1,230¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.5%¿Í 2.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ç¥º» ¼öÁý Ä«µå ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Çö´ë Áø´Ü¿¡¼­ Ç¥º» ¼öÁý Ä«µå°¡ Á¡Á¡ ´õ Áß¿äÇØÁö´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Ç¥º» ¼öÁý Ä«µå´Â ÁÖ·Î »ý¹°ÇÐÀû »ùÇÃÀÇ ¼öÁý, º¸°ü ¹× ¿î¼ÛÀ» ´Ü¼øÈ­ÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ Çö´ë ÀÇ·á Áø´Ü, °øÁß º¸°Ç ¸ð´ÏÅ͸µ ¹× »ý¹° ÀÇÇÐ ¿¬±¸¿¡ ÇʼöÀûÀÎ ÅøÀÌ µÇ¾ú½À´Ï´Ù. ÀÌ Ä«µå´Â °ÇÁ¶Ç÷Èç(DBS), Ÿ¾×, ÇùÃø ¼¼Æ÷ ¹× ±âŸ »ý¹°ÇÐÀû ¾×ü¸¦ ó¸®µÈ Á¾ÀÌ ¶Ç´Â ¸âºê·¹Àο¡ ¼öÁý ¹× ÀúÀåÇϵµ·Ï ¼³°èµÇ¾úÀ¸¸ç, ƯÈ÷ ¿ø°ÝÁö ¹× ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ¿¡¼­ Àúħ½ÀÀû, Àúºñ¿ë, ³í¸®ÀûÀ¸·Î È¿À²ÀûÀÎ ½Ã·á äÃë ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. Á¦°øÇÕ´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ºÐ»êÈ­¿Í ¿¹¹æ ÀÇ·á¿¡ Á¡Á¡ ´õ ÁßÁ¡À» µÎ´Â °¡¿îµ¥, Ç¥º» ¼öÁý Ä«µåÀÇ »ç¿ëÀº ½Å»ý¾Æ °ËÁø, °¨¿° ¸ð´ÏÅ͸µ, À¯ÀüÀÚ °Ë»ç, ¹ýÀÇÇÐ ºÐ¼®, ¸ÂÃãÇü ÀÇ·á µîÀÇ ¿ëµµ·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. »ó¿Â¿¡¼­ÀÇ ¾ÈÁ¤¼ºÀ¸·Î ÀÎÇØ ÄݵåüÀÎ ¹°·ù°¡ ºÒÇÊ¿äÇØÁ® º¹À⼺°ú ºñ¿ëÀ» ¸ðµÎ Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÆÒµ¥¹Í ½Ã´ë¿¡ ¿ìÆí °Ë»ç¿Í ÀÚÅà °Ëü äÃë°¡ °­Á¶µÇ¸é¼­ È®Àå °¡´ÉÇÑ Áø´Ü ¹× ¹ÙÀÌ¿À °¨½Ã Àü·«ÀÇ ÀÏȯÀ¸·Î °Ëü ¼öÁý Ä«µå°¡ °¢±¤À» ¹Þ°Ô µÇ¾ú½À´Ï´Ù. ÀÓ»ó½ÃÇè, ÇöÀå ±â¹Ý ¿ªÇÐ, ¿ø°ÝÀÇ·á ȯ°æ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ÀÌ Ä«µå´Â º¸´Ù Á¢±ÙÇϱ⠽±°í °­·ÂÇÑ °Ç°­ ¸ð´ÏÅ͸µ ÇÁ·¹ÀÓ¿öÅ©·ÎÀÇ ÀüȯÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

Ä«µå µðÀÚÀÎ ¹× ½Ã·á ¾ÈÁ¤¼ºÀÇ Çõ½ÅÀº ¾î¶»°Ô ½ÃÀå µµÀÔÀ» ÃËÁøÇϰí Àִ°¡?

¿©°úÁö ó¸®, ºÐ¼®¹° ¾ÈÁ¤È­, ´ÙÁß ½Ã·á ÅëÇÕÀÇ ±â¼ú ¹ßÀüÀº ½Ã·á ¼öÁý Ä«µåÀÇ ±â´ÉÀ» Çõ½ÅÀûÀ¸·Î º¯È­½Ã۰í ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº ÇöÀç ÇÙ»ê(DNA, RNA)°ú ´Ü¹éÁúÀ» º¸´Ù È¿°úÀûÀ¸·Î º¸Á¸Çϰí, º¸Á¸ ±â°£À» ¿¬ÀåÇϸç, ´Ù¾çÇÑ È¯°æ Á¶°Ç¿¡¼­ ºÐ¼®¹°ÀÇ ¹«°á¼ºÀ» Çâ»ó½ÃŰ´Â °­È­µÈ È­ÇÐÀû ÄÚÆÃÀÌ Àû¿ëµÈ Ä«µå¸¦ »ý»êÇϰí ÀÖ½À´Ï´Ù. ¿ë·® È®Àοë Áö½Ã¾àÀÌ ³»ÀåµÈ Ä«µåµµ ÀÖÀ¸¸ç, °¡Á¤ °Ë»ç³ª ÇöÀå ȯ°æ¿¡¼­ »ç¿ëÀÚ°¡ ÃæºÐÈ÷ ÀϰüµÈ »ùÇÃÀ» äÃëÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. ´Ù¸¥ Çõ½Å ±â¼ú·Î´Â ´Ù¾çÇÑ ½Ã·á À¯Çü¿¡ ´ëÀÀÇÏ´Â ´ÙÁß ±¸¿ª ¼öÁý ¿µ¿ª, ÃßÀû¼ºÀ» À§ÇÑ ÅëÇÕ ¹ÙÄÚµå, ¹ýÀÇÇÐ ¹× ÀÓ»óÀû »ç¿ëÀ» À§ÇÑ ±ÔÁ¦ Áؼö¿¡ ºÎÇÕÇÏ´Â º¯Á¶ ¹æÁö Æ÷Àå µîÀÌ ÀÖ½À´Ï´Ù. °¡Àå ³Î¸® »ç¿ëµÇ´Â °ÇÁ¶ Ç÷¾× ½ºÆÌ Ä«µå´Â PCR, Áú·®ºÐ¼®, ELISA, Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS) µîÀÇ ´Ù¿î½ºÆ®¸² ¿ëµµ¿¡ ÃÖÀûÈ­µÇ¾î °í°¨µµ Áø´Ü ¿öÅ©Ç÷ο쿡 ÀûÇÕÇÕ´Ï´Ù. ¶ÇÇÑ °Ë»ç½Ç¿¡¼­ÀÇ Ã³¸®¸¦ °£¼ÒÈ­Çϱâ À§ÇØ ÀÚµ¿È­ ´ëÀÀ Æ÷¸Ëµµ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç° ¼öÁØÀÇ °³¼±À¸·Î °Ëü ¼öÁý Ä«µå´Â ´õ¿í ´Ù¿ëµµÇϰí, »ç¿ëÀÚ Ä£È­ÀûÀ̸ç, Àü ¼¼°è Áø´Ü¾à °ø±Þ¸Á°úÀÇ È£È¯¼ºÀÌ ³ô¾ÆÁ³½À´Ï´Ù.

¼ö¿ä°¡ °¡Àå ¸¹ÀÌ Áõ°¡ÇÏ´Â °÷Àº ¾îµðÀ̸ç, ¾î¶² ÀÌ¿ë »ç·Ê°¡ ¼ºÀåÀ» ÁÖµµÇϰí Àִ°¡?

°Ëü äÃë Ä«µå¿¡ ´ëÇÑ ¼ö¿ä´Â ÀÓ»ó, ¿¬±¸, °øÁߺ¸°Ç ºÐ¾ß¿¡¼­ ºü¸£°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ½Å»ý¾Æ °ËÁø, °¨¿° Áø´Ü, À¯ÀüÀÚ °Ë»ç µîÀÇ ºÐ¾ß¿¡¼­ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ½Å»ý¾Æ ¼±º°°Ë»ç ÇÁ·Î±×·¥Àº ƯÈ÷ ºÏ¹Ì, À¯·´ ¹× ¾Æ½Ã¾ÆÅÂÆò¾ç ÀϺο¡¼­ ´ë»çÀÌ»ó ¹× À¯ÀüÀû ÀÌ»ó¿¡ ´ëÇÑ °Ë»ç¸¦ ÀÏ»óÀûÀ¸·Î ½ÃÇàÇϰí ÀÖ´Â ½Å»ý¾Æ ¼±º°°Ë»ç ÇÁ·Î±×·¥ Áß °ÇÇ÷Áõ ½ºÆÌ Ä«µåÀÇ °¡Àå Å« »ç¿ëÀÚ·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. HIV, °£¿°, °áÇÙ Á¶±â ¹ß°ß ÇÁ·Î±×·¥ÀÇ Àü ¼¼°è È®´ëµµ ±âÁ¸ÀÇ Ã¤Ç÷À̳ª ³ÃÀå »ùÇà ¿î¼ÛÀÌ Á¦ÇÑÀûÀÎ °³¹ßµµ»ó±¹¿¡¼­ÀÇ Ä«µå »ç¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Á÷Á¢ ÀÇ·Ú(DTC) À¯ÀüÀÚ °Ë»ç ȸ»çµéÀº Á¡Á¡ ´õ ¸¹Àº °¡Á¤¿ë äÇ÷ Ä«µå¸¦ ŰƮ¿¡ ÅëÇÕÇϰí ÀÖÀ¸¸ç, °í°´Àº °¡°è, °æ·Â °Ë»ç, °Ç°­ º¸°í¼­¸¦ À§ÇØ Å¸¾×À̳ª »´ ´ÛÀº ¾×ü »ùÇÃÀ» Á¦ÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¹ðÅ©¿Í Á¾´ÜÀû ÄÚȣƮ ¿¬±¸´Â °Ëü Ä«µå¸¦ »ç¿ëÇÏ¿© ´ë±Ô¸ð Áý´Ü¿¡¼­ °Ëü¸¦ ¼öÁý, º¸°ü, ÀúÀåÇÏ´Â ºñ¿ë È¿À²ÀûÀÎ ¹æ¹ýÀ¸·Î °Ëü¸¦ ¼öÁý, º¸°ü, º¸Á¸ÇÕ´Ï´Ù. ¾à¹°À¯ÀüüÇÐ, ¹ýÀÇÇÐ µ¶¼ºÇÐ, Ä¡·áÁ¦¹° ¸ð´ÏÅ͸µ°ú °°Àº »õ·Î¿î ºÐ¾ß¿¡¼­µµ ºñħ½ÀÀûÀ̰í È®Àå °¡´ÉÇÑ »ùÇøµÀ» À§ÇØ ÀÌ·¯ÇÑ ÅøÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ, NGO, ÇÐ°è ¿¬±¸ÀÚµéÀº ƯÈ÷ ´ë·® »ùÇøµ°ú °¨½Ã¸¦ ½Å¼ÓÇϰí È¿À²ÀûÀ¸·Î ¼öÇàÇØ¾ß ÇÏ´Â ¼¼°è º¸°Ç À§±â ÀÌÈÄ, ÃÑüÀûÀ¸·Î ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Ç¥º» ¼öÁý Ä«µå ½ÃÀåÀÇ Àå±âÀûÀÎ ¼ºÀå ¿øµ¿·ÂÀº?

Ç¥º» ¼öÁý Ä«µå ½ÃÀåÀÇ ¼ºÀåÀº ¼¼°è º¸°Ç ¿ì¼±¼øÀ§, Áø´ÜÀÇ ºÐ»êÈ­, ±â¼ú Çõ½Å, ±ÔÁ¦ ¹ßÀü°ú °ü·ÃµÈ ¿©·¯ °¡Áö ¿¬µ¿µÈ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº Á¶±â Áø´Ü, ¹ßº´ ÃßÀû ¹× °³º° Ä¡·á¸¦ Áö¿øÇÏ´Â È®Àå °¡´ÉÇÏ°í ºñ¿ë È¿À²ÀûÀÎ »ùÇà ¼öÁý Åø¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀçÅÃÄ¡·á, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ, µðÁöÅÐ Áø´ÜÀ¸·ÎÀÇ ÀüȯÀº ÀüÅëÀûÀÎ ÀÇ·á ȯ°æ ÀÌ¿ÜÀÇ °Ëü äÃ븦 À§ÇÑ ±âº» Åø·Î¼­ °Ëü Ä«µåÀÇ °ü·Ã¼ºÀ» ´õ¿í È®´ë½Ã۰í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ °Ë»ç, ÀÓ»ó ¿¬±¸, ¹ÙÀÌ¿À¹ðÅ©¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ºÐ¼®¹°ÀÇ ¹«°á¼ºÀÌ ³ô°í ´Ù¿î½ºÆ®¸² ºÐÀÚ ¿öÅ©Ç÷οì¿Í ȣȯµÇ´Â »ùÇÃÀ» ÀúÀåÇÒ ¼ö ÀÖ´Â Ä«µå¿¡ ´ëÇÑ Àå±âÀûÀÎ ¼ö¿ä°¡ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² °øÁߺ¸°Ç±â°üÀº °Ëü Ä«µå¸¦ ¿ªÇÐÁ¶»ç ¹× ¹é½Å Á¢Á¾ ¸ð´ÏÅ͸µ¿¡ ÅëÇÕÇÏ¿© Áý´Ü °Ç°­°ü¸®¿¡¼­ °Ëü Ä«µåÀÇ ¿ªÇÒÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÌ °ÇÁ¶ Ç÷¾× ¹ÝÁ¡ ¹× ´ëü °Ëü Ä«µå°¡ ÀÓ»ó µî±Þ µ¥ÀÌÅÍ ¼Ò½º·Î¼­ À¯È¿ÇÏ´Ù´Â Àνĵµ Áø´Ü¿¡¼­ °Ëü Ä«µå »ç¿ëÀ» Á¤»óÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. °Ç°­ ÇüÆò¼º, Áúº´ ¿¹¹æ, ½Å¼ÓÇÑ ´ëÀÀ ´É·ÂÀÌ Àü ¼¼°è¿¡¼­ ÁÖ¸ñ¹Þ°í ÀÖ´Â °¡¿îµ¥, °Ëü äÃë Ä«µå´Â Àü ¼¼°è ¾îµð¿¡¼­³ª ȯÀÚ¿Í °Ë»ç½Ç °£ÀÇ °ÝÂ÷¸¦ ÇØ¼ÒÇÏ´Â Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÉ °ÍÀÔ´Ï´Ù.

ºÎ¹®

°Ëü(Ç÷¾×, Ÿ¾×, ´¢, Çù¼¼Æ÷, ±âŸ), ¼ÒÀç(ÄÚÆ° & ¼¿·ê·Î¿À½º ±â¹Ý, ¼¶À¯ ±â¹Ý, ±âŸ), ¿ëµµ(½Å»ý¾Æ ½ºÅ©¸®´×, °¨¿°Áõ °Ë»ç, Ä¡·áÁ¦ ¸ð´ÏÅ͸µ, ¹ýÀÇÇÐ, Á¶»ç, À£ºù/°Ç°­ ¸ð´ÏÅ͸µ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Specimen Collection Cards Market to Reach US$559.7 Million by 2030

The global market for Specimen Collection Cards estimated at US$450.8 Million in the year 2024, is expected to reach US$559.7 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Blood, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$221.1 Million by the end of the analysis period. Growth in the Saliva segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$122.8 Million While China is Forecast to Grow at 6.8% CAGR

The Specimen Collection Cards market in the U.S. is estimated at US$122.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$112.3 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Specimen Collection Cards Market - Key Trends & Drivers Summarized

Why Are Specimen Collection Cards Gaining Critical Importance in Modern Diagnostics?

Specimen collection cards have become an essential tool in modern medical diagnostics, public health surveillance, and biomedical research, primarily due to their ability to simplify biological sample collection, preservation, and transportation. Designed to collect and store dried blood spots (DBS), saliva, buccal cells, or other biological fluids on treated paper or membranes, these cards offer a minimally invasive, low-cost, and logistically efficient solution for sample acquisition-especially in remote or resource-limited settings. With global healthcare systems increasingly focused on decentralization and preventive care, the use of specimen collection cards is expanding across applications such as newborn screening, infectious disease monitoring, genetic testing, forensic analysis, and even personalized medicine. Their stability at ambient temperatures eliminates the need for cold-chain logistics, reducing both complexity and cost. Moreover, the pandemic-era emphasis on mail-in testing and at-home sample collection has brought specimen collection cards into the spotlight as part of scalable diagnostics and bio-surveillance strategies. Whether in clinical trials, field-based epidemiology, or telehealth settings, these cards are supporting the global shift toward more accessible and resilient health monitoring frameworks.

How Are Innovations in Card Design and Sample Stability Enhancing Market Adoption?

Technological advancements in filter paper treatment, analyte stabilization, and multi-sample integration are transforming the capabilities of specimen collection cards. Manufacturers are now producing cards with enhanced chemical coatings that preserve nucleic acids (DNA, RNA) and proteins more effectively, extending shelf life and improving the integrity of analytes under varied environmental conditions. Some cards are embedded with indicator dyes for volume verification, ensuring sufficient and consistent sample collection by users in home-testing or field environments. Other innovations include multi-zone collection areas for different sample types, integrated barcoding for traceability, and tamper-evident packaging that meets regulatory compliance for forensic and clinical use. Dried blood spot cards, the most widely used format, are increasingly optimized for downstream applications such as PCR, mass spectrometry, ELISA, and next-generation sequencing (NGS), thereby aligning with high-sensitivity diagnostic workflows. Automation-compatible formats are also being developed to streamline laboratory processing. These product-level improvements are making specimen collection cards more versatile, user-friendly, and compatible with global diagnostic supply chains-key factors in enabling broader adoption in both high-throughput laboratories and point-of-care environments.

Where Is Demand Rising Fastest, and Which Use Cases Are Leading Growth?

Demand for specimen collection cards is rising rapidly across clinical, research, and public health sectors, with particularly strong growth in applications such as newborn screening, infectious disease diagnostics, and genetic testing. Newborn screening programs remain the largest and most established user of dried blood spot cards, especially in North America, Europe, and parts of Asia-Pacific, where testing for metabolic and genetic disorders is routine. The global expansion of early detection programs for HIV, hepatitis, and tuberculosis is also driving card usage in developing countries, where conventional phlebotomy and refrigerated sample transport may be limited. Direct-to-consumer (DTC) genetic testing companies are increasingly incorporating at-home collection cards into their kits, allowing customers to submit saliva or cheek swab samples for ancestry, carrier screening, or wellness reports. Biobanks and longitudinal cohort studies are using specimen cards to collect, store, and archive samples from large populations in a compact, cost-effective manner. Emerging areas like pharmacogenomics, forensic toxicology, and therapeutic drug monitoring are also adopting these tools for non-invasive, scalable sampling. Governments, NGOs, and academic researchers are collectively contributing to demand, particularly in the wake of global health crises where mass sampling and surveillance are needed quickly and efficiently.

What’s Driving the Long-term Growth of the Specimen Collection Cards Market?

The growth in the specimen collection cards market is driven by several interlinked factors tied to global health priorities, diagnostic decentralization, technological innovation, and regulatory evolution. A primary driver is the rising need for scalable, cost-effective sample collection tools that support early diagnosis, outbreak tracking, and personalized treatment-especially in low-resource or geographically dispersed populations. The shift toward home-based healthcare, remote patient monitoring, and digital diagnostics is further expanding the relevance of specimen cards as foundational tools for sample acquisition outside traditional healthcare settings. Increased investment in genetic testing, clinical research, and bio-banking is creating long-term demand for cards that can store samples with high analyte integrity and compatibility with downstream molecular workflows. In parallel, public health agencies are integrating specimen cards into epidemiological studies and vaccination monitoring, reinforcing their role in population health management. Regulatory recognition of dried blood spot and alternative specimen cards as valid sources for clinical-grade data is also helping to normalize their use in diagnostics. As global focus intensifies on health equity, disease prevention, and rapid response capabilities, specimen collection cards are set to remain a vital enabler-bridging the gap between patients and laboratories, wherever they are in the world.

SCOPE OF STUDY:

The report analyzes the Specimen Collection Cards market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Specimen (Blood, Saliva, Urine, Buccal Cells, Others); Material (Cotton & Cellulose-based, Fiber-based, Others); Application (New Born Screening, Infectious Diseases Testing, Therapeutic Drug Monitoring, Forensics, Research, Wellbeing / Health Monitoring, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â